Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03820947 · ClinicalTrials.gov registry record · NA
VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial
A NA study, sponsored by Medtronic Endovascular.
- Terminated
- Registry status
- NA
- Development phase
- 506
- Enrollment target
NCT03820947 is a NA study that was terminated before completion, run by Medtronic Endovascular. The registered enrollment target is 506 participants.
The verdict
NCT03820947, a NA study, was terminated before completion, sponsored by Medtronic Endovascular.
- TERMINATED
- Registry status
- NA
- Development phase
- 506 participants
- Enrollment target
Study Summary
Global, Post-Market, Prospective, Multi-Center, Randomized Controlled Trial of the VenaSeal™ Closure System vs. Surgical Stripping or Endothermal Ablation (ETA) for the Treatment of Early and Advanced Stage Superficial Venous Disease
Interventions
- DEVICE VenaSeal™ System
- DEVICE Endothermal Ablation (ETA)
- PROCEDURE Surgical Stripping
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 506 participants |
| Start Date | 2020-02-05 |
| Est. Completion | 2025-11-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03820947
The ClinicalTrials.gov registry entry for NCT03820947 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 506 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Endovascular, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which VenaSeal™ System is the first listed.
NCT03820947 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03820947 about?
NCT03820947 is a clinical study titled "VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial". Global, Post-Market, Prospective, Multi-Center, Randomized Controlled Trial of the VenaSeal™ Closure System vs. Surgical Stripping or Endothermal Ablation (ETA) for the Treatment of Early and Advanced Stage Superficial Venous Disease
What is the current status of trial NCT03820947?
This trial is currently terminated. It is a NA study. The enrollment target is 506 participants. The study started on 2020-02-05. Estimated completion is 2025-11-10.
What interventions are being tested in trial NCT03820947?
The interventions under investigation include: VenaSeal™ System (DEVICE), Endothermal Ablation (ETA) (DEVICE), Surgical Stripping (PROCEDURE).
Who is sponsoring clinical trial NCT03820947?
This trial is sponsored by Medtronic Endovascular, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.